The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

(2010) A. K. Gandhi et al.   CURRENT CANCER DRUG TARGETS

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

(2010) S K Kumar et al.   LEUKEMIA

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

(2010) Ross D. Brown et al.   LEUKEMIA & LYMPHOMA

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

(2009) Edward A. Stadtmauer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

(2009) Olaf Christensen et al.   JOURNAL OF IMMUNOTHERAPY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Treatment of Relapsed/Refractory Multiple Myeloma

(2009) Efstathios Kastritis et al.   SEMINARS IN HEMATOLOGY

Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma

(2008) O. C. Goodyear et al.   BLOOD

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

Lenalidomide: a novel anticancer drug with multiple modalities

(2008) Christine Galustian et al.   EXPERT OPINION ON PHARMACOTHERAPY